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The underlying events of how dendritic cells (DC) are capable of evoking an antigen-speciﬁc skin sen-
sitization response are not yet understood. Recently, we revealed a set of genes in human cord blood
CD34+ DC (CD34-DC) that show a discriminating behaviour after skin sensitizing exposure. Based on
their differential expression, an in vitro assay was developed to identify chemicals as sensitizing or not.
This study was designed to investigate the genes’ involvement in the DC response to skin sensitizers
and as such gain insights in the sensitization cascade.
Functional connection of the marker genes was inquired by constructing a molecular network using
Ingenuity software. By real-time RT-qPCR, we established the effective expression of 3 additional geneovel biomarkers transcripts in the generated network in CD34-DC, of which CREB1 and TNF-˛ were signiﬁcantly altered
in expression by sensitizing versus non-sensitizing exposure.
Next, itwas testedwhether thediscriminating responseof CCR2andCOX2marker geneswas translated
at the protein level in CD34-DC exposed to 3 sensitizers versus 3 non-sensitizers. Signiﬁcantly differential
protein expression of CCR2 and COX2 was conﬁrmed using ﬂow cytometry.
Our results indicate that the marker genes may be functionally relevant in DC mediated skin sensiti-
zation.. Introduction
Skin sensitization is characterized by a series of critical events
ollowing skin contact with a substance of low-molecular weight.
endritic cells (DC)act asorchestrators in thisby recognizing, inter-
alizing, processing andﬁnally presenting chemical haptens as true
ntigens on their surface (Banchereau and Steinman, 1998). This
licits an immune response by activation of naïve T cells (Cella et
l., 1997).
Dendritic-like cells derived from human primary sources are
aluable in vitro cell models to mimic in vivo skin DC. The main
rimary-derived human DC models are generated either from
uman CD14+ peripheral blood monocytes (CD14-DC) (Lenz et al.,
993; Romani et al., 1994; Sallusto and Lanzavecchia, 1994) or from
ord blood or bone marrow-derived CD34+ hematopoietic precur-
ors (CD34-DC) (Caux et al., 1996; Inaba et al., 1992). These in vitro
∗ Corresponding author at: Flemish Institute for Technological Research (VITO
.V.), Environmental Risk and Health Unit, Toxicology, Boeretang 200, 2400 Mol,
elgium. Tel.: +32 14 33 51 07; fax: +32 14 58 26 57.
E-mail address: nathalie.lambrechts@vito.be (N. Lambrechts).
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models respond to sensitizing chemicals andmay be useful for haz-
ard identiﬁcation of skin sensitizers (Ryan et al., 2007). The key to
successful identiﬁcation of such chemicals is a test system based
upondiscriminatingmarkers that are relevant in the biology of skin
sensitization. Although our understanding of these immunologi-
cal mechanisms remains far from complete, multiple biomarkers
in primary DC have been proposed to represent crucial events
in DC mediated skin sensitization. After antigen-capturing and -
processing, DC present the antigen on their surface by engaging
in a maturation program which includes morphological, pheno-
typic and functional changes (Saint-Mezard et al., 2004). Increased
expression of co-stimulatory surfacemolecules has been examined
extensively and CD86 appears to be the most promising marker
in primary DC (dos Santos et al., 2009). Also changes in cytokine
secretion such as IL-1 occur upon DC maturation. These signal-
ing molecules have been explored as well as possible biomarkers
for chemical-induced sensitization (dos Santos et al., 2009). How-
ever, response patterns of both surface and cytokine biomarkers
have indicated that their expressionproﬁleshavea limiteddynamic
range and may be chemical-dependent, which is not sufﬁcient for
the identiﬁcation of all sensitizers (Casati et al., 2005). Transcript
proﬁling is a more recent approach that allows to detect genomic
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ngerprints that are induced in DC by chemical sensitizers, leading
o novel and unique potential biomarkers of DC interaction with
hese compounds (Cluzel-Tailhardat et al., 2007; Ryan et al., 2004;
choeters et al., 2007; Szameit et al., 2008, 2009). Using microarray
xperiments on exposed CD34-DC, we reported the identiﬁcation
f a novel gene set that has a highly signiﬁcant capability to dis-
inguish chemical skin sensitizers from non-sensitizers (Schoeters
t al., 2007). Discriminant analysis of the expression changes of
selected set of these markers after CD34-DC exposure to an
xtended set of 21 chemicals, resulted in the VITOSENS® classiﬁca-
ion assaywith anaccuracyof 89%, speciﬁcity of 97%, and sensitivity
f 82% based on 73 samples (Hooyberghs et al., 2008).1
Understanding the mechanisms through which chemical aller-
ens induce contact sensitization in humans is indispensable for
ssessing this toxicological effect without the need for animal
esting. Consequently, in this study the mechanism by which the
ITOSENS® assay recognizes skin sensitizing chemicals was inves-
igated. First, a literature-based network connecting the 13 novel
iomarkers for sensitizing exposure of CD34-DC was constructed.
xpression of potentially relevant members of this network was
valuated by real-time RT-qPCR. In addition, the expression of a
onﬁned selection of the 13 biomarkerswas investigated at protein
evel.
. Materials and methods
.1. Pathway analysis
.1.1. Network generation
Thirteen genes (ABCA6, AQP3, CCR2, CCR7, COX2, CREM, CXCR4, ENC, MAD, NINJ,
BEF1, PSCDBP and SLC2A3) (Hooyberghs et al., 2008) were imported into IPA
.5 (Ingenuity Systems, Inc., Mountain View, USA) to generate a putative cellular
etwork based on the largemanually curated knowledge database of pathway inter-
ctions extracted from the literature. The HUGO Gene Symbols of the marker genes
ere entered in the IPA database as input for analysis by the ‘my pathways’ option.
elationships between the 13 biomarkers were created by the ‘connect’ tool based
n information contained in Ingenuity’s Knowledge Base. Subsequently, molecules
ere added to this pathway in order to connect all 13 molecules with maxi-
um1 intermediatemolecule by the option ‘Path Explorer− Shortest Path/Shortest
ath +1’. These network eligiblemoleculeswere algorithmically generated based on
heir connectivity. A detailed description on the statistics behind the interactions
an be found at www.ingenuity.com. Three criteria were set before adding rela-
ionships and molecules. First, both direct and indirect relationships were allowed.
econd, only molecules that were previously described in human immune related
rimary cells, cell lines, and epidermal tissue were considered for pathway analysis.
nd third, except for biologic drugs and any sort of chemical, all types of interaction
olecules were accepted in the network.
Using the ‘overlay canonical pathway’ tool, we identiﬁed the ‘well recognized’
r ‘canonical’ pathways of which a molecule was present in the generated network.
rom the gene ontology annotations in the IPA ‘molecule summary’, the function of
he molecules could be derived.
.1.2. Real-time RT-qPCR
In the software-generated network, cAMP responsive element binding pro-
ein (CREB)1, nuclear factor of kappa light polypeptide gene enhancer in B cells
p105) (NF-B)1, and tumour necrosis factor  (TNF-˛) were selected to con-
rm their active involvement as pathway members because of their interactions
ith VITOSENS® biomarkers and relevant biological roles. cDNA samples from
he exposure experiments described by Hooyberghs et al. (2008) were used. The
amples were conﬁned to those exposed compounds that were classiﬁed cor-
ectly by the VITOSENS® assay. The test set of skin sensitizing chemicals included
mmoniumhexachloroplatinate IV (HCPt), cinnamaldehyde (CA), dinitrochloroben-
ene (DNCB), 2,4-dinitrobenzenesulfonic acid (DNBS), dinitroﬂuorobenzene (DNFB),
ugenol, nickel sulfate (NiSO4), 2-mercaptobenzothiazole (2-MBT), and tetram-
thylthiuram disulﬁde (TMTD). The 5 non-sensitizers were represented by methyl
alicylate (MeSA), para-aminobenzoic acid (pABA), phenol, sodium dodecyl sulfate
SDS), and zinc sulfate (ZnSO4). In our previous study, all chemicals were applied to
he cells at a concentration that induced 20% cell growth inhibition, except forMeSA
nd pABA which were used at the highest soluble concentration (Hooyberghs et al.,
008). DC cultures from3 different donorswere used for each test substance, except
fter treatment with DNCB where DC from only 2 donors were analyzed. This led to
1 This assay is currently patent pending (WO/2008/037806).Letters 196 (2010) 95–103
a total number of 41 donor samples in this analysis that were each exposed for 6,
11, and 24h.
Real-time RT-qPCR was performed on 20ng cDNA with the LightCycler® 480
SYBR Green I Master mix (2×) (Roche Applied Science, Mannheim, Germany) on
a LightCycler® 480 Instrument (Roche Applied Science) according to instructions
of the manufacturer. For each sample 5 reference genes were measured (GAPDH,
HPRT, SDHA, RPLI3A, YWHAZ). Primers were designed using Primer Express® Soft-
ware v3.0 from Applied Biosystems (Halle, Belgium) and thoroughly tested (primer
sequences are available upon request). Gene expression changes were analyzed
using the Biogazelle qBasePlus software (www.qbaseplus.com Biogazelle, Ghent,
Belgium) (Hellemans et al., 2007). Gene expression changes were determined as
fold-changes of exposed samples over corresponding solvent control samples. They
were transformed by a 2-base logarithm and addressed further as logarithmic fold-
changes (LFC). A LFC of 1 and −1 is representative for a fold-change of 2 and 0.5,
respectively.
Comparisons of the induced LFC for CREB1,NF-B1, and TNF-˛ between skin sen-
sitizer andnon-sensitizer exposeddonorswereperformedusing a1-tailed Student’s
t-test for samples with unequal variances. A p<0.05 was considered statistically
signiﬁcant for all analyses.
Visual presentation in a heatmap of the mean LFC in CD34-DC was done
by TM4 Software Suite: TIGR MultiExperiment Viewer v4.0 (http://www.tm4.
org/mev.html).
2.2. Protein detection
2.2.1. Generation of CD34+ progenitor-derived DC
CD34+-cell isolation and culture procedures have been described before
(Schoeters et al., 2007). Brieﬂy, human cord blood samples were collected from the
umbilical blood vessels of placentas of normal, full-term infants. Informed consent
was given by the mothers and the study was approved by the ethical commission
of the Heilig Hart hospital in Mol, Belgium and the St. Dimpna Hospital in Geel,
Belgium. Mononuclear cells were separated from the cord blood by density gra-
dient centrifugation and subsequently CD34+ progenitor cells were extracted by
positive immunomagnetic selection. These cells were cultured in Iscove’s modiﬁed
Dulbecco’smedium (IMDM) in the presence of TNF- (RocheApplied Science, Upper
Bavaria, Germany), GM-CSF (Gentaur, Brussels, Belgium), SCF (Biosource, Nivelles,
Belgium) and IL-4 (Biosource) to induce proliferation and differentiation towards
immature CD34-DC according to the method described by Lardon et al. (1997).
2.2.2. Chemical exposure of CD34-DC
At the end of the 12-day culture period, immature DC from each donor were
exposed in 6-well plates to a conﬁned selection of chemicals: 3 sensitizers (DNFB
(11M), dihydroquinone (DHQ) (59M), 2-MBT (420M)), and 3 non-sensitizers
(dimethylsulfoxide (DMSO) (64M),MeSA (822M), and ZnSO4 (440M) (all from
Sigma–Aldrich except for DMSO that was obtained from LabScan Ltd, Dublin, Ire-
land) for 24 and 48h. The concentrations used in exposure experiments yielded
around 80% cell viability at 24h, as previously determined on at least 3 biological
replicates (Hooyberghs et al., 2008; Lambrechts et al., 2010). Since no cytotoxicity
was found for MeSA, this compound was used at the highest soluble concentration.
For each chemical and its corresponding solvent, 3 independent exposure exper-
iments were performed. The chemicals were dissolved in culture medium (DHQ,
DMSO and ZnSO4) or prepared in a 100% DMSO stock solution and then further
diluted in medium up to a ﬁnal 0.05% (v/v) DMSO concentration (DNFB, 2-MBT and
MeSA). Viability of the cells after 24 and 48h of exposure was assessed using pro-
pidium iodide staining and ﬂow cytometry since phenotypical analyses needed to
be performed on cells with a viability of at least 70%.
2.2.3. Flow cytometry
After chemical treatment, the protein expression of intracellular CCR2 and COX2
together with the well-known DC surface markers HLA-DR, CD86, and CD83 was
evaluatedusingﬂowcytometric experiments. COX2was chosen for its central role in
the network whereas CCR2 was selected for its high discriminating power between
skin sensitizers andnon-sensitizers (Hooyberghs et al., 2008). The chemokine recep-
tor CCR2 exists as 2 isoforms (CCR2a andCCR2b) as a result of alternate splicing from
the same gene (Charo et al., 1994). The differentially expressed transcript that we
previously identiﬁed by microarray analysis is the CCR2a variant which is known
to be located predominantly in the cytoplasm (Wong et al., 1997). The antibody
we used, anti-CCR2-PE (clone 48607.211) (R&D Systems, Minneapolis, USA), cannot
discriminate between both isoforms and therefore was used to detect both CCR2a
and CCR2b. Total CCR2 expression was measured using intracellular staining on
permeabilized cells because this results in the labeling of both surface (CCR2b) and
intracellular protein (CCR2a). CCR2b expression was quantiﬁed by surface staining
of non-permeabilized cells. We than considered expression of CCR2a as the differ-
ence of total CCR2 and CCR2b. For simplicity in the text, CCR2a is further referred to
as CCR2.
Todetermine expressionof surface proteins after 24 and48hof exposure, CD34-
DCwereharvested and suspended at 1×105 cells in 50l PBS− with1% (w/v) bovine
serum albumin (BSA; Sigma–Aldrich). Cells were then incubated for 30min at 4 ◦C
with 2l of antibody, except anti-CCR2-PE of which 10l was added. For intra-
cellular staining of CCR2 and COX2, cells were ﬁrst permeabilized in FACS Lysing
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Fig. 1. Human cellular network comprising 13 VITOSENS® biomarkers. Thirteen VITOSENS® biomarkers (yellow) were loaded into the Ingenuity Pathways Analysis software
and a human cellular network based on peer-reviewed literature ﬁndings was built around them. Forty-four molecules were added to connect the 13 biomarkers of which
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he arrow indicates the direction of inﬂuence the molecules act upon each other. Th
iomarkers.
olution (BD Biosciences; San Jose, USA) with 0.2% (w/v) saponin (Sigma–Aldrich)
uring 10min at room temperature. After washing the cells in 1ml PBS− with 1%
w/v) BSA and 0.1% (w/v) saponin, they were suspended in 1×105 cells in 50l
BS− with 1% (w/v) BSA and 0.1% (w/v) saponin. From then on, the same pro-
edure was followed as for surface staining, except for the antibody-incubation
hich occurred at room temperature. The following monoclonal antibodies were
sed: anti-HLA-DR-phycoerythrin (PE) (clone L243), anti-CD83-PE (clone HB15e),
nti-CD86-PE (clone IT2.2), anti-COX-2-PE (clone AS67) (BD Biosciences) and anti-
CR2-PE (clone 48607.211) (R&D Systems). Isotypic control antibodies IgG1-PE,
gG2b-PE and IgG2-PE (BD Biosciences) were used to estimate the non-speciﬁc
inding. Afterwashing, cells were resuspended in PBS− with 1% (v/v) formaldehyde.
low cytometric analysis was performed on a FACSCalibur (BD Biosciences).
CD34-DC were identiﬁed by light scatter, gates were set to exclude dead cells
nd cell debris,whichweredeterminedusingpropidium iodide stainingandﬂuores-
ence histograms were evaluated using CellQuest (BD Biosciences). To verify for any
bnormality, isotypic controlsweremeasured and evaluated to stain only 0.5% posi-
ive cells. Percentages of positive cells above this 0.5% and the geomeanﬂuorescence
ntensity (MFI)were calculated. For assessmentof phenotypical changes stimulation
ndices (SI) were calculated as follows: (% positive cells×MFI) of chemical-treated
ells, divided by (% positive cells×MFI) of time-related control cells. The resulting SI
ata were transformed by a 2-base logarithm and further addressed as log2 SI. Theextra-cellular. CREM and COX2 represent highly interconnected molecules in the
ation of mRNA expression in (non-)sensitizer exposed CD34-DC. The direction of
k lines represent the interactions of CREB1, NF-B1 and TNF-with the VITOSENS®
mean log2 SI value of all 3 sensitizers and non-sensitizers was calculated (±SEM)
and tested for signiﬁcant increases in response using a 2-sample equal variance 1-
tailed Student t-test. Values were considered signiﬁcant when the p-value was less
than 0.05.
3. Results
3.1. Network analysis
To explore the mechanism by which the VITOSENS® classi-
ﬁcation model recognizes skin sensitizing chemicals, Ingenuity
Pathways Analysis (IPA) was used to organize 13 genes with highly
discriminating power into a network of interacting molecules. In
Fig. 1 all molecules are presented as yellow nodes in their respec-
tive cellular compartment, and the lines in between themrepresent
their interactions. Based on ﬁndings from the large Ingenuity peer-
reviewed literature database, the software added 44 molecules to
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Table 1
Member molecules of the VITOSENS®-based cellular network The member molecules that were added by the IPA software are listed below in alphabetical order with their
HUGO gene symbol, Entrez gene name, and function that may be relevant in the context of skin sensitization. The VITOSENS® biomarkers are indicated in bold and the
additionally analyzed network molecules in italic.
Symbol Entrez gene name Functions
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 ATP binding
ADORA2A Adenosine A2a receptor Cell-mediated immune response
ADRBK2 Adrenergic, beta, receptor kinase 2 Signal transducer activity
AQP3 Aquaporin 3 (Gill blood group) Water channel activity: positive regulation of immune system
ATF1 Activating transcription factor 1 Transcription factor activity
CAV1 Caveolin 1, caveolae protein, 22kDa Negative regulation of cytokine-mediated signaling pathway
CCL2 Chemokine (C–C motif) ligand 2 Antigen presentation, cell-mediated immune response
CCL5 Chemokine (C–C motif) ligand 5 Antigen presentation, cell-mediated immune response
CCR2 Chemokine (C–C motif) receptor 2 Antigen presentation
CCR5 Chemokine (C–C motif) receptor 5 Antigen presentation, cell-mediated immune response
CCR7 Chemokine (C–C motif) receptor 7 Antigen presentation, cell-mediated immune response
CEBPB CCAAT/enhancer binding protein (C/EBP), beta Cell-mediated immune response
CREB1 cAMP responsive element binding protein 1 Cell-mediated immune response
COX2 Cyclooxygenase (prostaglandin-endoperoxide synthase 2 and
prostaglandin G/H synthase)
Dermatological disorder, antigen presentation, cell-mediated
immune response
CREBBP CREB binding protein Cell-mediated immune response
CREM cAMP responsive element modulator Transcription factor activity
CSF2 Colony stimulating factor 2 (granulocyte–macrophage) Dermatological disorder, antigen presentation, cell-mediated
immune response
CXCL12 Chemokine (C–X–C motif) ligand 12 (stromal cell-derived
factor 1)
Antigen presentation, cell-mediated immune response
CXCR4 Chemokine (C–X–C motif) receptor 4 Dermatological disorder, antigen presentation, cell-mediated
immune response
PSCDBP Cytohesin 1 interacting protein Regulation of cell adhesion
EDN1 Endothelin 1 Antigen presentation
EGR1 Early growth response 1 Cell-mediated immune response
ENC1 Ectodermal-neural cortex (with BTB-like domain) Protein binding
EP300 E1A binding protein p300 Cell-mediated immune response
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog Dermatological disorder, cell-mediated immune response
GNAQ Guanine nucleotide binding protein (G-protein), q polypeptide G-protein coupled receptor protein signaling pathway
HDAC1 Histone deacetylase 1 Transcription factor activity
HDAC2 Histone deacetylase 2 Transcription factor activity
IFNG Interferon, gamma Dermatological disorder, antigen presentation, cell-mediated
immune response
IGF1R Insulin-like growth factor 1 receptor Cell-mediated immune response
IL-2 Interleukin 2 Antigen presentation, cell-mediated immune response
IL-4 Interleukin 4 Dermatological disorder, antigen presentation, cell-mediated
immune response
IL-6 Interleukin 6 (interferon, beta 2) Dermatological disorder, antigen presentation, cell-mediated
immune response
IL-8 Interleukin 8 Dermatological disorder, antigen presentation, cell-mediated
immune response
IL-1 Interleukin 1, beta Dermatological disorder, antigen presentation, cell-mediated
immune response
INSR Insulin receptor Dermatological disorder
JAK2 Janus kinase 2 G-protein coupled receptor protein signaling pathway
JUN Jun oncogene Dermatological disorder, cell-mediated immune response
MAPK3 Mitogen-activated protein kinase 3 Cell-mediated immune response
MXD1 MAX dimerization protein 1 Transcription factor activity
PBEF1 Pre-B-cell colony-enhancing factor 1 Cytokine activity
NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 Cell-mediated immune response
NFˇ1 Nuclear factor of kappa light polypeptide gene enhancer in B
cells 1
Dermatological disorder, cell-mediated immune response
NINJ1 Ninjurin 1 Cell adhesion
NOS2 Nitric oxide synthase 2, inducible Antigen presentation
PLD2 Phospholipase D2 Receptor-mediated endocytosis
POMC Proopiomelanocortin Dermatological disorder, antigen presentation, cell-mediated
immune response
PTGER2 Prostaglandin E receptor 2 (subtype EP2), 53kDa G-protein coupled receptor protein signaling pathway
PTGER4 Prostaglandin E receptor 4 (subtype EP4) G-protein coupled receptor protein signaling pathway
RARB Retinoic acid receptor, beta Dermatological disorder
RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian) Dermatological disorder, cell-mediated immune response
SLC2A3 Solute carrier family 2 (facilitated glucose transporter),
member 3
Substrate-speciﬁc transmembrane transporter activity
STAT3 Signal transducer and activator of transcription 3 (acute-phase
response factor)
Dermatological disorder, antigen presentation, cell-mediated
immune response
TBP TATA box binding protein Transcription factor activity
TNF Tumor necrosis factor (TNF superfamily, member 2) Dermatological disorder, antigen presentation, cell-mediated
immune response
TP53 Tumor protein p53 Dermatological disorder, cell-mediated immune response
VEGFA Vascular endothelial growth factor A Dermatological disorder, antigen presentation, cell-mediated
immune response
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Table 2
Canonical pathways involved in the VITOSENS®-based cellular network. The canonical pathways that are associated with the network generated by the IPA software and
contained at least 10 network molecules. The pathways are ranked below according to the number and mentioning the names of involved molecules.
Canonical pathway name # Molecules
Glucocorticoid receptor signaling 24 CCL2, CCL5, CEBPB, CREB1, CREBBP, CSF2, EP300, FOS, IFN,
IL-2, IL-4, IL-6, IL-8, IL-1, JAK2, JUN, MAPK3, NF-1,
NOS2, POMC, RELA (includes EG:5970), STAT3, TBP, TNF
IL-6 signaling 12 CEBPB, FOS, IL-6, IL-8, IL-1, JAK2, JUN, MAPK3, NF-1,
RELA (includes EG:5970), STAT3, TNF
Aryl hydrocarbon receptor signaling 12 EP300, FOS, IL-6, IL-1, JUN, MAPK3, NFE2L2, NF-1,
RARB, RELA (includes EG:5970), TNF, TP53
Renin–angiotensin signaling 12 CCL2, CCL5, FOS, GNAQ, JAK2, JUN, MAPK3, NF-1,
PTGER2, RELA (includes EG:5970), STAT3, TNF
Trem1 signaling 11 CCL2, CSF2, IL-6, IL-8, IL-1, JAK2, MAPK3, NF-1, RELA
(includes EG:5970), STAT3, TNF
IL-12 signaling and production in macrophages 11 CEBPB, EP300, FOS, IFNG, IL-4, JUN, MAPK3, NF-1, NOS2,
RELA (includes EG:5970), TNF
PPAR/RXR activation 11 CREBBP, EP300, GNAQ, IL-6, IL-1, INSR, JAK2, JUN, MAPK3,
NF-1, RELA (includes EG:5970)
IL-17 signaling 11 CCL2, CEBPB, COX2, IL-6, IL-8, JAK2, JUN, MAPK3, NF-1,
NOS2, RELA (includes EG:5970)
Production of nitric oxide and reactive oxygen species in macrophages 11 CREBBP, FOS, IFNG, IL-4, JAK2, JUN, MAPK3, NF-1, NOS2,
RELA (includes EG:5970), TNF
Acute-phase response signaling 11 CEBPB, FOS, IL-6, IL-1, JAK2, JUN, MAPK3, NF-1, RELA
(includes EG:5970), STAT3, TNF
Dendritic cell maturation 10 CCR7, CREB1, CSF2, IL-6, IL-1, JAK2, MAPK3, NF-1,
RELA (includes EG:5970), TNF
Xenobiotic metabolism signaling 10 CREBBP, EP300, IL-6, IL-1B, MAPK3, NFE2L2, NF-1,
NOS2, RELA (includes EG:5970), TNF
Communication between innate and adaptive immune cells 10 CCL5, CCR7, CSF2, IFN, IL-2, IL-4, IL-6, IL-8, IL-1, TNF
PPAR signaling 10 CREBBP, EP300, FOS, IL-1, INSR, JUN, MAPK3, NF-1,
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he original set of 13 marker genes in the network. Overall, the
reated interactome contained 20 nuclear molecules, 7 network
embers in the cellular cytoplasm, 15 molecules were located in
he cell’s plasma membrane, and the remaining 15 nodes were
ituated in the extra-cellular space.
In the network presented, COX2 is in a central position being
nﬂuenced by a large number of network members and perse-
ering itself. COX2 interferes with the VITOSENS® biomarkers
CR7 and chemokine (C–X–C motif) receptor (CXCR) 4, and is
irectly regulated via a feedback loop and transcription factors,
uch as nuclear factor (erythroid-derived 2)-like 2 (Nfe2l2 or
rf2), and indirectly via CREM and MAX dimerization protein
MXD)1. Also CREM, CXCR4 and CCR2 appear to be highly inter-
onnected with other nodes in the network. CXCR4 interconnects
ith CCR2 and COX2, and CCR2 also regulates its own expres-
ion.
For each member of the network, a description of the name and
unction is listed in Table 1. Twenty-six of 57 network molecules
ere functionally involved in antigen presentation, 33 in cell-
ediated immune responses and 20 in dermatological disorders.
verlaying the network with canonical pathways showed that
he network molecules took part in 180 different canonical path-
ays. The pathways containing 10 or more member molecules
re represented in Table 2 and included relevant cascades for
kin sensitization, like glucocorticoid (GC) receptor signaling (24
olecules), IL-12 signaling (11), and DC maturation (10). Some of
he molecules are present in multiple pathways of which not nec-
ssarily all are related to skin sensitization. As such, these pathways
ere removed from Table 2: colorectal cancer metastasis signaling
17), hepatic ﬁbrosis (15), molecular mechanisms of cancer (10),
nd Huntington’s disease signaling (10).
Biological relevance of the network in exposed CD34-DC was
eriﬁed by measuring the expression of 3 member genes other
han the 13 genetic markers, using real-time RT-qPCR on the same
D34-DC samples that were used to develop the VITOSENS® classi-RELA (includes EG:5970), TNF
10 COX2, CREB1, FOS, JUN, MAPK3, NF-1, NOS2, RELA
(includes EG:5970), TNF, VEGFA
ﬁcation model. cAMP responsive element binding protein (CREB)1,
nuclear factor of kappa light polypeptide gene enhancer in B
cells (p105) (NF-B)1, and tumour necrosis factor  (TNF-˛) were
selectedbecause of thenumber of connectionswith theVITOSENS®
biomarkers (indicated in black in Fig. 1) and because their biologi-
cal role was highly relevant for the skin sensitization process (see
Section 4).
The samples used in this study had been exposed to 9 skin
sensitizing compounds (2-MBT, CA, DNCB, DNBS, DNFB, eugenol,
HCPt, NiSO4, and TMTD) and 5 non-sensitizers (MeSA, pABA,
phenol, SDS, and ZnSO4) (Hooyberghs et al., 2008). Expression
of all 3 genes could be detected in both skin sensitizer and
non-sensitizer exposed CD34-DC and the induced mean LFC are
visualized in a heatmap (Fig. 2). From this, it can be observed
that CREB1 showed strongest stimulation after 11 and 24h of
skin sensitizing exposure but at the latter time point, also non-
sensitizers induced expression of this gene. Overall expression
of NF-B1 is inhibited by skin sensitizers, except for NiSO4 and
2-MBT which seem to induce expression of this gene at 11h,
and 11 and 24h of exposure, respectively. Of the non-sensitizers,
SDS and pABA slightly stimulate NF-B1 expression. TNF-˛ on
the other hand, is up-regulated by all skin sensitizers and for
most of them after 11 and 24h of exposure, except for NiSO4
who again starts to inhibit expression of this molecule after 24h
treatment. The non-sensitizing substances seem to induce a sim-
ilar expression proﬁle for this molecule, but the stimulation is
limited.
When comparing the LFC of these 3 genes in CD34-DC after sen-
sitizing versus non-sensitizing treatment (Fig. 3), the stimulation of
CREB1 was signiﬁcantly lower after 24h of skin sensitizing versus
non-sensitizing exposure (p=0.045). On the contrary, expression of
TNF-˛ was signiﬁcantly induced by sensitizers compared to non-
sensitizers after 11h treatment (p=0.003). NF-B1 did not show
a signiﬁcantly different expression proﬁle between the 2 sets of
chemicals.
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Fig. 2. Differential gene expression of 3 VITOSENS®-based network members. Expression changes of CREB1, NF-B1, and TNF- genes in CD34-DC were analyzed using
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.2. Protein detection
To evaluate whether the VITOSENS® genes were actually
ranslated into proteins we analyzed the expression of the intra-
ellular proteins CCR2 and COX2 which may play a central role
s suggested by the network analysis. Preliminary experiments
n time kinetics going from 6 to 96h of exposure were ﬁrst
erformed and 24 and 48h of exposure appeared to contain
he most relevant information (data not shown). After 24 and
8h of exposure of CD34-DC to 3 sensitizers (DHQ, DNFB and
-MBT) versus 3 non-sensitizers (DMSO, MeSA, and ZnSO4), dif-
erential expression of CCR2 and COX2 was evaluated by means
f ﬂow cytometry. As a control for DC activation, the surface
arkers HLA-DR, CD86, and CD83 were also evaluated. Exposing
D34-DC for 24h to sensitizing chemicals induced a signiﬁcant
ise in expression of HLA-DR (p=0.0002), COX2 (p=0.04), and
CR2 (p=0.02) compared to non-sensitizing exposure (Fig. 4a).
fter 48h of sensitizing treatment, again HLA-DR (p=0.004),
OX2 (p=0.006), and also CD86 (p=0.02) showed signiﬁcantly
igher expression levels compared to non-sensitizing exposure
Fig. 4b). Overall, the protein expression of the DC activation
arkers and COX2 was induced by chemical sensitizers relative
o solvent, while CCR2 expression was inhibited. Non-sensitizing
hemicals did not exert noticeable changes on marker expression
log2 SI < |0.5|).
ig. 3. Differential gene expression of CREB1, NF-B1 and TNF-. CD34-DC were exposed
MTD) (black) and 5 non-sensitizers (MeSA, pABA, phenol, SDS, ZnSO4) (grey) during 6, 1
o the chemicals’ solvent was measured using real-time RT-qPCR and is presented as the
verage of 3 biological donor samples. Signiﬁcant differences in expression between sensskin sensitizers (HCPt, CA, DNCB, DNBS, DNFB, eugenol, NiSO4, 2-MBT, and TMTD),
d in a heatmap and are indicated by a gradient of green and red color, as shown in
een color down-regulated gene expression.
4. Discussion
The objective of this study was to acquire knowledge on the
mechanism by which the VITOSENS® assay is able to discrimi-
nate skin sensitizing from non-sensitizing chemicals. VITOSENS®
is based on the expression of CREM and CCR2, and along with these
molecules, 11 others were observed to behave highly discriminat-
ing in the molecular cascade in CD34-DC upon sensitizing versus
non-sensitizing exposure.
Using the IPA software, possible relationships between the 13
VITOSENS® biomarkers were investigated. Screening the literature
ﬁndings, the software integrated themolecules in a virtual network
containing 57 molecules, out of which 26 were involved in antigen
presentation. Further, it appeared that the network contained 24
molecules that are involved in GC receptor signaling, 11 members
take part in IL-12 signaling and that the DC maturation pathway
overlaps with 10 network molecules. Besides DC maturation, IL-
12 signaling is known to occur in antigen-presenting DC (Martin
et al., 2008; Saint-Mezard et al., 2004) and GC promote migra-
tion of cutaneous DC into the lymph nodes and T cell-mediated
immunity (Kamimura et al., 2009). This indicates that the network
constructed on the basis of the VITOSENS® biomarkers contains
members that may be relevant for DC mediated skin sensitization.
A central effector role in the network was revealed for COX2.
COX2 is thekeyenzyme inprostaglandinbiosynthesis and is known
to 9 chemical skin sensitizers (2-MBT, CA, eugenol, DNBS, DNCB, DNFB, HCPt, NiSO4,
1 and 24h. Their mean differential expression after chemical exposure as opposed
mean LFC± SEM. For each chemical, exposure experiments were performed on an
itizing and non-sensitizing exposure are indicated with an *p<0.05.
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Fig. 4. Differential protein expression of DC maturation markers, COX2 and CCR2.
CD34-DC were exposed for 24h (a) and 48h (b) to 3 sensitizers (DNFB, DHQ, and 2-
MBT) and 3 non-sensitizers (DMSO, MeSA, and ZnSO4). Each chemical was applied
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Translation of the COX2 protein was signiﬁcantly elevated byn 3 independent donor samples. After ﬂow cytometry analysis, the differential
rotein expression was considered as the mean log2 stimulation index (SI)± SEM
fter exposure to (non-)sensitizers relative to their solvent. Signiﬁcant differences
etween sensitizing and non-sensitizing exposures (p<0.05) are indicated with *.
o be associated with biologic events such as injury, inﬂammation,
nd proliferation (Hla and Neilson, 1992; Tazawa et al., 1994). In
he network, Nrf2 directly inﬂuences COX2 which might explain
he stimulation of this enzyme in our CD34-DC model after expo-
ure to sensitizers. Indeed, the Nrf2 pathway has been described
requently to be induced by chemical sensitizers (Ade et al., 2009;
atsch and Emter, 2008). Further, CREM and CCR2, the VITOSENS®
eneswith highest discriminating power (Hooyberghs et al., 2008),
ere also highly interconnected with other molecules in the gen-
rated network. The observation that the transcription modulator
REM was a central node in the network could be explained by its
ole as point of potential convergence formultiple intracellular sig-
aling cascades (Mayr and Montminy, 2001). The high number of
nteractions thatwere establishedbyCOX2 andCREM indicated that
hesemoleculesmightbehighly relevant in coordinatingmolecular
vents in sensitizer exposed CD34-DC.
To verify whether ‘key signaling molecules’ as indicated by the
n silico network analysis were actually expressed in our DC model,
eal-time RT-qPCR experiments were performed on CREB1, NF-B1
nd TNF-˛. These molecules were selected due to their connections
ith the VITOSENS® biomarkers and their biological relevance for
ensitization related processes.
CREB1 directly affects solute carrier family 2 (facilitated glucose
ransporter) member 3 (SLC2A3) and COX2, and is inﬂuenced by
REM, the most discriminating gene in (non-)sensitizing exposed
D34-DC (Hooyberghs et al., 2008). Like CREM, CREB1 is a mem-
er of the cAMP responsive element (CRE) nuclear factor family
Solomou et al., 2001) and it has been established before that
RE-dependent transcription positively regulates cell adhesion,
ncluding the molecule CD54, during human myeloid differenti-
tion (Saeki et al., 2003). Furthermore, CREB1 is involved in theLetters 196 (2010) 95–103 101
transcription of immune regulatory genes, such as TNF-˛, IL-2,
COX2, and IL-6 (Mayr and Montminy, 2001). This may explain the
detectable and up-regulated levels of CREB1 expression in CD34-
DC after 11 and 24h of skin sensitizing exposure relative to solvent
exposure. Skin sensitizers induced a more rapid expression of
CREB1 (after 11h), as opposed to the non-sensitizers which cause
a signiﬁcantly stronger stimulation only after 24h of exposure.
NF-B1 is amemberof theNF-Bgroupwhichhasbeen reported
previously to be involved in the intracellular cascade induced
by skin sensitizers (Ade et al., 2007). This molecule regulates
COX2 and is inﬂuenced by CXCR4. In our results, we could not
observe a signiﬁcant difference of NF-B1 expression after sen-
sitizing versus non-sensitizing exposure. This was due in part to
the large inter-compound variation that was observed for this
gene after sensitizing exposure. It has been reported frequently
that different chemicals may trigger different activation routes in
antigen-presenting cells (Ade et al., 2007; Boisleve et al., 2005;
Koeper et al., 2007; Miyazawa et al., 2008; Takanami-Ohnishi et
al., 2002) and this may explain why for instance NiSO4 and 2-MBT
strongly induce NF-B1 at few time points as opposed to the other
sensitizing chemicals.
TNF-˛ is the 3rd network member that was selected to be ana-
lyzed since it is a key regulator of the inﬂammatory response and
since it is connected to 8 nodes in the network. It was previ-
ously shown that TNF- is constitutively expressed by CD34-DC
and that production could be enhanced by treatment of the cells
with chemical sensitizers such as nickel chloride (De Smedt et al.,
2001). This was conﬁrmed by our results where TNF-˛ is signiﬁ-
cantly up-regulated after 11h of skin sensitizing exposure versus
non-sensitizing chemicals.
The identiﬁcation of these additionalmolecularmarkersmay be
relevant for further exploration of the biological pathways that are
associated with chemical-induced skin sensitization.
Based on their high discriminating power and central roles in
thenetwork, theVITOSENS® biomarker genes CCR2 andCOX2were
selected for further functional analysis. By performing ﬂow cytom-
etry experiments on skin sensitizer and non-sensitizer exposed
CD34-DC,wewanted to investigatewhether thebiomarkergenesof
CCR2 and COX2were translated into proteins that showed a similar
differential expression pattern. Also, DC surface markers HLA-DR,
CD83 and CD86 were evaluated for checking a sensitizer induced
maturation status. Expression of CD86 and HLA-DR was signiﬁ-
cantly increased after sensitizing exposure as opposed to treatment
with non-sensitizers. This was expected since HLA-DR and CD86
are well-known DC maturation markers and in earlier studies we
observed their up-regulationafter exposureofCD34-DC tomultiple
sensitizers (De Smedt et al., 2001, 2005). While as expected the dif-
ferential expressionof thesematurationmarkers provedpositive in
our cell model, the expression of the novel skin sensitization mark-
ers CCR2 and COX2 appeared to be even more pronounced at the
protein level. CCR2 encodes a transmembrane monocyte chemoat-
tractant protein receptor (Wong et al., 1997). Protein expression
of CCR2 was signiﬁcantly reduced after 24h of sensitizing treat-
ment of CD34-DC, whereas the expression after non-sensitizing
exposure was not altered. The differential expression of the CCR2
protein indicates that itmay exert a functional role in DC activation
by chemical skin sensitization. A possible role may be the fact that
after exposure to inﬂammatory stimuli, immature DC respond to
macrophage-derived chemokines through CCR2, but upon matura-
tion DC loose the responsiveness to these chemokines by receptor
downregulation or desensitization (Merad et al., 2002).sensitizing chemicals compared to non-sensitizers at both time
points. Harizi et al. (2001) already indicated that this regulator of
prostaglandin E2 (PGE2) synthesis might play a role in antigen pre-
sentation in DC exposed to lipopolysaccharide. PGE2 is referred to
1 ology
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s apotent Th2-promoting factor (Goodwin, 1989),while chemical-
nduced skin sensitization is claimed to be Th1-mediated (Kimber
nd Dearman, 2002). Such contradictory results may be due to
GE2’s quite complex actions on immune inﬂammatory response
Harizi and Gualde, 2005), as well as to the different nature of the
timulus and of the species from which DC were derived.
In future experiments the functional role of these markers and
f other interesting molecules such as CREM, will be further inves-
igated.
Altogether, several conclusions can be drawn from our study.
irst, relationships between 13 VITOSENS® biomarkers were iden-
iﬁed in a network that might effectively be activated after skin
ensitizing chemical exposure of CD34-DC as was shown by the
ifferential expression of CREB1 and TNF-˛. Based on these results,
REM and COX2 appeared to be potential regulators in skin sen-
itization pathways in DC. Next, we established the signiﬁcantly
ifferential protein expression of this COX2 molecule, as well as
f the highly discriminating CCR2 marker in sensitizer versus non-
ensitizer induced CD34-DC. Besides these 2markers, investigation
f other molecules such as CREM might further add in the mecha-
istic insights of the VITOSENS assay®.
This research illustrates that novel biomarker genes that were
dentiﬁed in sensitizer exposed CD34-DC using genomics are actu-
lly translated into proteins, and therefore they may take part in
he biological process by which DC activate and present chemical
aptens to naïve T cells.
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